Stock Events

Maat Pharma. 

€8.7
10
-€0.02-0.23% Today

Statistics

Day High
8.88
Day Low
8.6
52W High
9.9
52W Low
4.5
Volume
935
Avg. Volume
1,599
Mkt Cap
101.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

11AprExpected
Q3 2021
Q1 2022
Q3 2022
Q1 2023
Q3 2023
Q1 2024
-0.48
-0.32
-0.16
0
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MAAT.PA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Serve Robotics
SERV
Mkt Cap5.4B
Seres Therapeutics, Inc. focuses on microbiome therapeutics, directly competing in the same space as Maat Pharma with its microbiome restoration therapy products.
Regenxbio
RGNX
Mkt Cap769.48M
REGENXBIO Inc. is involved in gene therapy, which includes treatments that could overlap with Maat Pharma's microbiome-based approaches for certain diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap101.91B
Vertex Pharmaceuticals Incorporated works on creating new therapies for treating cystic fibrosis and other serious diseases, potentially competing in indications Maat Pharma targets with its microbiome solutions.
Synlogic
SYBX
Mkt Cap21.78M
Synlogic, Inc. is pioneering synthetic biotic medicines, directly competing in the innovative treatment space, including microbiome engineering, similar to Maat Pharma's focus.
Forte Biosciences
FBRX
Mkt Cap26.71M
Fortress Biotech, Inc. is involved in the development of novel pharmaceutical therapies, including areas that might overlap with Maat Pharma's microbiome therapeutic applications.
Evelo Biosciences
EVLO
Mkt Cap0
Evelo Biosciences, Inc. focuses on developing microbiome-based therapies, making it a direct competitor in the field of microbiome science like Maat Pharma.
Seres Therapeutics
MCRB
Mkt Cap84.55M
Seres Therapeutics, Inc. (duplicate entry for SERV, focusing on microbiome therapeutics, directly competing with Maat Pharma in microbiome restoration therapy products).
Ardelyx
ARDX
Mkt Cap1.51B
Ardelyx, Inc. develops drugs for gastrointestinal and cardio-renal diseases, areas where microbiome therapies developed by Maat Pharma could be applied.
Galmed Pharmaceuticals
GLMD
Mkt Cap1.88M
Galmed Pharmaceuticals Ltd. works on liver diseases and metabolic disorders, potentially competing with Maat Pharma's microbiome-based treatments for similar conditions.
Ngm Biopharmaceuticals
NGM
Mkt Cap128.53M
NGM Biopharmaceuticals, Inc. is engaged in discovering and developing novel therapeutics in oncology, metabolism, and liver diseases, areas that might intersect with Maat Pharma's therapeutic focus.

About

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Show more...
CEO
Mr. Herve Affagard
Employees
52
Country
FR
ISIN
FR0012634822
WKN
000A3C7A5

Listings